There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
Kow, C. S., Zaidi, S. T. R., & Hasan, S. S. (2020). Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. American Journal of Cardiovascular Drugs, 20(3), 217-221. https://doi.org/10.1007/s40256-020-00406-0